Get the Stockscreener App
1.69
3.43%
-0.06
After Hours:
1.77
0.08
+4.73%
Nrx Pharmaceuticals Inc stock is traded at $1.69, with a volume of 84,273.
It is down -3.43% in the last 24 hours and down -9.63% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$1.75
Open:
$1.8
24h Volume:
84,273
Relative Volume:
1.08
Market Cap:
$18.81M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-2.9649
EPS:
-0.57
Net Cash Flow:
$-21.66M
1W Performance:
+2.42%
1M Performance:
-9.63%
6M Performance:
-64.19%
1Y Performance:
-35.00%
1-Day Range:
$1.65
$1.80
1-Week Range:
$1.60
$1.80
52-Week Range:
$1.59
$7.333
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRX-100 (Ketamine) Reaches Stability Milestone - Contract Pharma
NRx reports stable ketamine for suicidal depression treatment - Investing.com
NRx reports stable ketamine for suicidal depression treatment By Investing.com - Investing.com Canada
NRx Pharmaceuticals Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - citybiz
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) - StockTitan
NRx Pharmaceuticals Featured on Psychiatrist.com - citybiz
NRXP stock touches 52-week low at $1.59 amid market challenges - Investing.com
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 5.2% - Defense World
Energy Vault Holdings Inc (NRGV) expanding its growth trajectory ahead - SETE News
Market Insights: Recursion Pharmaceuticals Inc (RXRX)’s Notable Gain of 1.65, Closing at 6.76 - The Dwinnex
Rocket Pharmaceuticals’ (RCKT) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
The Significance of Moving Averages in Recursion Pharmaceuticals Inc Inc. (RXRX) Price Performance - The InvestChronicle
Meeder Advisory Services Inc. Increases Stake in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Market Update: Energy Vault Holdings Inc (NRGV) Sees Negative Movement, Closing at 0.79 - The Dwinnex
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight - MSN
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by State of New Jersey Common Pension Fund D - Defense World
Reneo Pharmaceuticals Inc (RPHM) rating downgrades by Leerink Partners - Knox Daily
Reneo Pharmaceuticals executive buys shares worth over $484k By Investing.com - Investing.com Canada
Recursion Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
A look into Recursion Pharmaceuticals Inc (RXRX)’s deeper side - SETE News
Do you want to know where to find good stock? Take a look at Recursion Pharmaceuticals Inc’s (NASDAQ:RXRX) Sentiment Analysis – US Post News - US Post News
January 2027 Options Now Available For NRG Energy - Nasdaq
Metric Analysis: Royalty Pharma plc (RPRX)’s Key Ratios in the Limelight - The Dwinnex
Market Resilience: Reneo Pharmaceuticals Inc (RPHM) Finishes Weak at 1.31, Down -7.09 - The Dwinnex
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight - MyChesCo
Forsta AP Fonden Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Royal London Asset Management Ltd. - Defense World
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics' (NMRA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
NRG Energy, Inc. (NRG): A Very Important AI Stock According to BlackRock - Insider Monkey
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com - Morningstar
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com - PR Newswire
NRx Pharmaceuticals and HOPE Therapeutics Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - citybiz
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - Nasdaq
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, I - GuruFocus.com
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) and HOPE Therapeutics, Inc. Announce Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - PR Newswire
NRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q2 2024 - MSN
NRx Pharma Subsidiary HOPE Therapeutics Secures $30M to Buy Ketamine Clinics - citybiz
NRx Pharmaceuticals reports potential acquisition and financing agreements - MSN
HOPE Therapeutics secures $30 million for clinic acquisitions - Investing.com India
HOPE Therapeutics Secures Financing Ketamine Clinic ExpansionNRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga
Plans for New Acquisition of Clinics Generating $100 Million - openPR
HOPE Therapeutics secures $30 million for clinic acquisitions - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics - PR Newswire
NRx Pharmaceuticals begins search for new CEO - Investing.com
NRX Pharmaceuticals Seeks New CEO for Drug Launches - TipRanks
NRx Pharmaceuticals begins search for new CEO By Investing.com - Investing.com UK
NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer - Marketscreener.com
NRx Pharmaceuticals Reports Second Quarter and Year-to-Date 2024 Financial Results and Business Update - MyChesCo
NRx Pharmaceuticals Secures $16 Million in Convertible Debt Financing - MSN
NRx Pharmaceuticals Secures $16 Million in Convertible Debt Financing - MyChesCo
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):